Cocrystal PharmaNASDAQ: COCP

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.

Cocrystal Pharma is in the Healthcare sector

Cocrystal Pharma is in the Biotechnology industry

Cocrystal Pharma is headquartered in United States

Cocrystal Pharma initial public offering (IPO) was on 22 February 2012

https://www.cocrystalpharma.com

No, Cocrystal Pharma is not included in the S&P 500 index

No, Cocrystal Pharma is not included in the NASDAQ 100 index

No, Cocrystal Pharma is not included in the Dow Jones index